profit from every $100 of sales.
$0$100
Elanco Animal Health
$26.48-1.05% today
+15.8% in 1 year
1-year low $19.801-year high $26.84
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Elanco Animal Health sold, what it kept, and what it did with the cash.
Sales went from $4.41 billion in 2022 to $4.72 billion in 2025, with -$232 million of profit last year.
SalesProfit
Elanco Animal Health vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Elanco Animal Health | No profit yet | ||
 Merck KGaA | 25.3× · Fair price | ||
 Takeda Pharmaceutical | 98.8× · Very expensive | ||
 Galderma Group | 89.1× · Very expensive | ||
 Teva Pharmaceutical Industries | 35.8× · Expensive |
AI analysis
An AI analyst reads Elanco Animal Health's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 3,273 | 4,764 | 4,411 | 4,417 | 4,439 | 4,715 | |
| 1,606 | 2,632 | 2,498 | 2,486 | 2,436 | 2,593 | |
| – | – | 384 | 326 | 251 | 252 | |
| -10 | 381 | 851 | -224 | 1,385 | 676 | |
| -574 | -483 | -78 | -1,231 | 338 | -232 | |
| -1.30 | -0.99 | -0.15 | -2.50 | 0.68 | -0.47 | |
| 49.1% | 55.2% | 56.6% | 56.3% | 54.9% | 55.0% | |
| – | – | 8.7% | 7.4% | 5.7% | 5.3% | |
| -17.5% | -10.1% | -1.8% | -27.9% | 7.6% | -4.9% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 17,693 | 16,478 | 15,491 | 14,362 | 12,614 | 13,358 |
| Cash | 495 | 638 | 345 | 352 | 468 | 545 |
| Total debt | 6,127 | 6,319 | 5,836 | 5,774 | 4,321 | 4,017 |
| Total liabilities | 9,217 | 8,970 | 8,202 | 8,139 | 6,518 | 6,811 |
| 8,457 | 7,508 | 7,289 | 6,223 | 6,096 | 6,547 | |
| 441 | 487 | 488 | 492 | 497 | 496 | |
| -2.9% | -1.9% | 1.0% | -6.0% | 5.5% | -0.0% | |
| -6.8% | -6.4% | -1.1% | -19.8% | 5.5% | -3.5% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -41 | 483 | 452 | 271 | 541 | 560 | |
| 135 | 159 | 184 | 140 | 147 | 276 | |
| -176 | 324 | 268 | 131 | 394 | 284 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | – | – | – | – | |
| 47 | 66 | 59 | 46 | 55 | 68 |
Valuation
- –
- 25.7×
- –
- 1.5×
- 2.8×
- 46.6×
- 24.7×
- 2.1%
- -1.8%
- 0.0%
Profitability
- 55.0%
- 5.3%
- -4.9%
- 15.4%
- 3.8%
- -2.7%
- -3.6%
- -1.8%
- 3.8%
- 7.6%
Growth
- +7.6%
- –
- −27.9%
- –
- +0.5%
Financial health
- 4.7×
- 0.61
- 30.2%
- 1.6×
- 2.16
- 1.12
- 0.37
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 43%of 959
Bottom 38%of 888
Bottom 39%of 889
Top 42%of 987
What analysts expect
- Average price target
- $27.88
- Range
- $22.00 – $30.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 0.40 | 0.34 | +17.6% |
| Feb 24, 2026 | 0.13 | 0.11 | +18.2% |
| Nov 5, 2025 | 0.19 | 0.13 | +46.2% |
| Aug 7, 2025 | 0.26 | 0.20 | +30.0% |
| May 7, 2025 | 0.37 | 0.31 | +19.4% |
| Feb 25, 2025 | 0.14 | 0.16 | −12.5% |
| Nov 7, 2024 | 0.13 | 0.12 | +8.3% |
| Aug 8, 2024 | 0.30 | 0.24 | +25.0% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
22No pass
Benjamin Graham
49No pass
Philip Fisher
30No pass
Peter Lynch
36No pass
Joel Greenblatt
0No pass
Charlie Munger
23No pass
Terry Smith
20No pass
Questions about Elanco Animal Health
Is Elanco Animal Health a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Elanco Animal Health AI analysis
What does Elanco Animal Health do?
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It is in Drug Manufacturers - Specialty & Generic, based in Indianapolis, IN, United States, with 9,400 employees.
Does Elanco Animal Health pay a dividend?
No. Elanco Animal Health does not pay a dividend at the moment.
Is Elanco Animal Health stock halal?
No. Elanco Animal Health does not pass our halal screen: more than 5% of its revenue comes from impermissible activities. How we check
How has Elanco Animal Health stock done over the past year?
Up 15.8% over the past twelve months, to $26.48. It traded between $19.80 and $26.84, close to its high.
Who are Elanco Animal Health's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Elanco Animal Health's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.